Market Overview

QIAGEN Reports Results for Second Quarter and First Half of 2018

  • Solid Q2 2018 performance:
    • Net sales of $377.2 million (+8% actual, +6% at constant
      exchange rates, or CER) vs. 5-6% CER guidance
    • Operating income margin of 14% of sales; adjusted operating
      income margin rises to 27% of net sales, driven by 2.2 percentage
      points improvement at CER
    • EPS of $0.16; adjusted EPS $0.33 ($0.33 CER) vs. ~$0.31-0.32
      CER guidance
    • Free cash flow rises 98% to $94.1 million
  • Advancing our Sample to Insight portfolio:
    • QuantiFERON latent TB test delivers solid double-digit CER
      growth; new international guidelines affirm the value of screening
      with modern blood test
    • QIAstat-Dx receives very positive customer response in Europe
      as next-generation syndromic testing platform
    • NGS-related sales set to achieve 2018 target for more than $140
      million on growth from GeneReader NGS System and platform-agnostic
  • QIAGEN reaffirms 2018 outlook for growth in net sales and adjusted

QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard:QIA)) announced results
of operations for the second quarter and first half of 2018, delivering
on the target for net sales growth and exceeding on adjusted earnings
per share while driving the expansion of its Sample to Insight portfolio
of molecular testing solutions.

"Our results for the second quarter of 2018 demonstrated a solid
performance and further progress toward our goals for an exciting year
of growth," said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V.
"We are on track to achieve our targets for higher sales and adjusted
earnings while building momentum across our Sample to Insight portfolio
and creating value for our customers and stakeholders."

Please find the full press release here

View Comments and Join the Discussion!